Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 52 of 102, showing 5 Applications out of 506 total, starting on record 256, ending on 260

# Protocol No Study Title Investigator(s) & Site(s)

256.

ECCT/22/08/02   AIM-LVRNA009-II_III-01
    A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 2/3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) for the Prevention of COVID-19 in Participants Aged 18 Years and Olde   
Principal Investigator(s)
1. Bernhards Ogutu
2. Lucas Otieno
3. Videlis Nduba
4. Bernhards Ogutu
5. Jacqueline Mirera
6. Jacqueline Mirera
Site(s) in Kenya
1. Siaya Clinical Trials Unit (Siaya county)
2. Homa Bay Clinical Trials Unit (Homa Bay county)
3. Ahero Clinical Trials Unit (Kisumu county)
4. CREA-N Machakos (Machakos county)
5. CREA-N Nakuru (Nakuru county)
6. Victoria Biomedical Research Institue (Kisumu county)
 
View

257.

ECCT/21/03/01   Recombinant COVID-19 vaccine
    A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells), for the prevention of COVID-19 in adults aged 18 years and older   
Principal Investigator(s)
1. Walter Jaoko Jaoko
Site(s) in Kenya
KAVI-institute of Clinical Research
 
View

258.

ECCT/22/03/04   VIBRI COVID-19-001/2021
    A Multi-Centre, Randomized, Double Blind, Phase 2b Trial to Evaluate the Safety and Immunogenicity of Janssen Ad26COVS1 and Novavax NVX-CoV2373 COVID-19 vaccines for Homologous and Heterologous Boosting in Adolescents and Adults Aged 12 to 64 Years with and without HIV infection in 3 African Countries (Kenya, Democratic Republic of Congo, and Rwanda).   
Principal Investigator(s)
1. Dr. Lucas Otieno Tina
Site(s) in Kenya
Victoria Biomedical Research Institute,
 
View

259.

ECCT/20/12/03   CALINA STUDY
    A multicenter, open-label, single-arm study to evaluate the PK, safety, tolerability and efficacy of a new artemether-lumefantrine (2.5 mg:30 mg) dispersible tablet in the treatment of infants and neonates <5 kg body weight with acute uncomplicated Plasmodium falciparum malaria.   Study number: CCOA566B2307   
Principal Investigator(s)
1. Benhards Ragama Ogutu
Site(s) in Kenya
KEMRI-Centre for Clinical Research (CCR)
 
View

260.

ECCT/24/10/03   EDE Scanner Study
    A non-interventional clinical validation study of the Exponential Deep Examination (EDE) scanner in the detection of human immunodeficiency virus (HIV), tuberculosis (TB) and malaria   
Principal Investigator(s)
1. VIDELIS Nduba
2. Berngards Ogutu
Site(s) in Kenya
1. Ahero Clinical Trials Unit (Kisumu county)
2. KEMRI/CRDR Siaya Clinical trials Annex (Siaya county)
3. VICTORIA BIOMEDICAL RESEARCH INSTITUTE (Kisumu county)
 
View